Onkológia S1/2019

Favourable therapeutic response of enzalutamide in patient with metastatic castration resistant prostate cancer

Chemotherapy with docetaxel (CHTH) was the standard treatment of metastatic castration resistant prostate cancer (mCRPC) until 2014. Nowdays, after androgen deprivation therapy (ADT) has failed, there is possibility for ARTA treatment (androgen receptor targed agents), which has proved its efficacy not only in prolonging of overall survival, but also in better tolerability compared to CHTH (without the risk of febril neutropaenia). This case report describes current management of a patient suffering from progresion of prostate cancer since the diagnosis had been made till the ARTA treatment was ceased.

Keywords: metastatic castration resistant prostate cancer, enzalutamide, indication criteria for ARTA treatment